23andMe, once a pioneer in direct-to-consumer (DTC) genetic testing, is now facing one of the most challenging moments in its history. The company is grappling with financial losses, a rapidly declining stock price, and recently announced a 1-for-20 reverse stock split. This move is seen as a last-ditch effort to stay listed on the Nasdaq Continue reading